AndhraNews.net
Home » Features » Companies » Novartis

Novartis


About Novartis

Novartis International AG is a global pharmaceutical company. The company is based in Basel, Switzerland.

Novartis is ranked second in sales among the worldwide pharmaceutical industry in 2010.

Novartis in News

Iran's Pharmaceutical Sector to Become a Pharma Powerhouse Post Sanction Era - Biotechnology Sector to Have Lucrative Opportunities
Business Wire IndiaWith annual consumption of 30 billion units of various generic medicines, Iran, the second-biggest consumer of generics in the Asian continent spent over USD 4.5 billion on drugs in 2015

NeoBiocon Partners with Novartis to Offer Vildagliptin for Diabetics in UAE
Business Wire IndiaNeoBiocon, a collaboration between Asia’s leading biopharmaceuticals company Biocon Ltd and Dr. B.R. Shetty, Chairman of the UAE-based Neopharma, announced today that it has partnered with Novartis Middle East FZE, to market Jalra (Vildagliptin) and Jalra-M (Vildagliptin + Metformin) in UAE

Novartis announces NEJM publication of two major trials showing significant efficacy of Cosentyx in ankylosing spondylitis patients
Novartis International AG /Novartis announces NEJM publication of two major trials showing significant efficacy of Cosentyx in ankylosing spondylitis patients . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Vernalis Announces Successful Completion of CCP-07 Pivotal Single-Dose Comparative Bioavailability Study
Vernalis plc (LSE: VER) (OTC PINK: VNLPY)

ABLYNX COMPLETES ENROLMENT OF THE FIRST-IN-INFANT PHASE I/IIa SAFETY STUDY WITH ITS ANTI-RSV NANOBODY AND EXTENDS THE TRIAL FOR YOUNGER INFANTS

BrightScope Announces Its Seventh Annual Top 30 401k Plans List
BrightScope (www.brightscope.com), a leading provider of independent financial information and investment research, is proud to announce the seventh BrightScope year-end ranking of the Top 30 401k Plans List to recognize companies with the best 401k plans containing more than $1 billion in assets.

OptimizeRx Corporation Appoints James Brooks as SVP of Business Development
ROCHESTER, MI--(Marketwired - December 15, 2015) - OptimizeRx Corp. (OTCQB: OPRX), a software company whose premier content-delivery platform enables pharmaceutical companies to provide on-demand patient-care services, has appointed James Brooks to the new position of senior vice president of business development, effective January 4, 2016.

Proteostasis Therapeutics, Inc. Announces Management Changes to Strengthen Research and Development Organization
Proteostasis Therapeutics, Inc. (PTI), a biopharmaceutical company developing small molecule therapeutics to treat diseases caused by defects in protein processing, announced today that Ben Munoz, Ph.D. has been promoted to Senior Vice President, Drug Discovery. PTI also announced the promotion of Po-Shun Lee, M.D. to Executive Vice President. Dr

Six Key Buyer Trends Reshaping MedTech Selling and Pricing
REDWOOD CITY, CA--(Marketwired - December 09, 2015) - Model N, Inc. (NYSE: MODN), the leading provider of cloud-based Revenue Management solutions to life science, technology and manufacturing companies, released the results of a study focused on the buying trends reshaping the MedTech industry

300 million child-friendly antimalarial treatments supplied without profit by Novartis
Novartis International AG /300 million child-friendly antimalarial treatments supplied without profit by Novartis . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Leading Pharmaceutical Companies Attend the Model N Regulatory Summit
REDWOOD CITY, CA--(Marketwired - December 08, 2015) - Model N, Inc. (NYSE: MODN), the leading provider of cloud-based Revenue Management solutions to life science, technology and manufacturing companies, announces the Regulatory Summit on December 9, 2015 at the Tre Piani in Princeton, NJ to discuss new rulings and best practices for the pharmaceutical industry.

Sandoz advances its biosimilars program with European Medicines Agency (EMA) acceptance of regulatory submission for biosimilar etanercept
Novartis International AG /Sandoz advances its biosimilars program with European Medicines Agency (EMA) acceptance of regulatory submission for biosimilar etanercept . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Novartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL
Novartis International AG /Novartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Phase III data shows Sandoz' proposed biosimilar pegfilgrastim has similar safety and efficacy as the reference product
Novartis International AG /Phase III data shows Sandoz' proposed biosimilar pegfilgrastim has similar safety and efficacy as the reference product . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Genuine Promotes Maris Hanson to SVP/Chief of Staff
Genuine, the digital agency distinguished by its "invent together," user-first approach, today announced it has promoted Maris Hanson to SVP/Chief of Staff. Since joining Genuine as VP of Talent in 2011, Hanson has helped grow Genuine's talent pool by more than 100 percent while also assuming responsibility for agency operations and a significant role in agency strategy.

Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations
Novartis International AG /Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Novartis announces new CTL019 study data demonstrating overall response in adult patients with certain types of lymphoma
Novartis International AG /Novartis announces new CTL019 study data demonstrating overall response in adult patients with certain types of lymphoma . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Novartis announces Phase III studies of Jakavi show disease improvement in patients with myelofibrosis and polycythemia vera
Novartis International AG /Novartis announces Phase III studies of Jakavi show disease improvement in patients with myelofibrosis and polycythemia vera . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Molecular Diagnostics Market Worth $9.50 Billion by 2022: Grand View Research, Inc.
The global molecular diagnostics market is expected to reach over USD 9.50 billion by 2022, according to a new report by Grand View Research Inc. Growing prevalence of chronic diseases and infections such as HPV and influenza is anticipated to be the key driver for molecular diagnostics market growth

Vernalis plc ("Vernalis" or the "Company") AGM Statement
Vernalis plc (LSE: VER) (OTC PINK: VNLPY) will hold its Annual General Meeting ("AGM") in London at 10.30am today. The Company issues the following statement ahead of the AGM:

First in the world regulatory approval of Novartis' Cosentyx(TM) in Japan for both psoriasis and psoriatic arthritis
Novartis International AG /First in the world regulatory approval of Novartis' Cosentyx(TM) in Japan for both psoriasis and psoriatic arthritis . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Alcon treatment Travatan® receives EU approval for pediatric glaucoma patients
Novartis International AG /Alcon treatment Travatan® receives EU approval for pediatric glaucoma patients. Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

MorphoSys Announces Clinical Milestone in Oncology Program
MorphoSys AG /MorphoSys Announces Clinical Milestone in Oncology Program. Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Vernalis plc: Update on AUY922 Development Programme
Vernalis plc (LSE: VER)

Model N to Sponsor European Pricing Platform Life Sciences Executive Briefing in Zurich
REDWOOD CITY, CA--(Marketwired - December 17, 2014) - Model N, Inc. (NYSE: MODN), the leading Revenue Management Cloud solutions provider to the life science and technology industries, announced today its sponsorship of the EPP Life Sciences Executive Briefing in Zurich, Switzerland on Jan. 22, 2015

Prima BioMed Completes Immutep Acquisition
Prima BioMed Ltd (NASDAQ: PBMD) (ASX: PRR) ("Prima" or the "Company") announces that the acquisition of Immutep SA ("Immutep"), the French privately owned biopharmaceutical company in the rapidly growing field of Immuno-Oncology, has been completed.

BrightScope Announces Its Sixth Annual Top 30 401k Plans List
BrightScope (www.brightscope.com), a leading provider of independent financial information and investment research, is proud to announce the sixth BrightScope year-end ranking of the Top 30 401k Plans List to recognize companies with the best 401k plans containing more than $1 billion in assets.

ABLYNX OPENS RECRUITMENT FOR FIRST-IN-INFANT PHASE IIa STUDY WITH ITS ANTI-RSV NANOBODY, ALX-0171

Model N Selected by Fairchild Semiconductor to Manage the Full Design to Revenue Lifecycle
REDWOOD CITY, CA--(Marketwired - December 16, 2014) - Model N, Inc

Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder
Novartis International AG /Novartis gains FDA approval for Signifor® LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Novartis announces results of trial evaluating the use of Afinitor® in first-line treatment in HER2+ advanced breast cancer at SABCS
Novartis International AG /Novartis announces results of trial evaluating the use of Afinitor® in first-line treatment in HER2+ advanced breast cancer at SABCS . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Head-to-head psoriasis study demonstrates superiority of Novartis Cosentyx(TM) to Stelara® in clearing skin
Novartis International AG /Head-to-head psoriasis study demonstrates superiority of Novartis Cosentyx(TM) to Stelara® in clearing skin . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Novartis announces safety and efficacy benefit of Jakavi® in global clinical trial of over 1,000 patients with myelofibrosis
Novartis International AG /Novartis announces safety and efficacy benefit of Jakavi® in global clinical trial of over 1,000 patients with myelofibrosis . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Six-year pivotal study data reinforce the superiority of Tasigna® over Glivec® in newly-diagnosed patients with Ph+ CML
Novartis International AG /Six-year pivotal study data reinforce the superiority of Tasigna® over Glivec® in newly-diagnosed patients with Ph+ CML . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

ADDITIONAL CLINICAL DATA FROM THE PHASE II STUDY WITH ABLYNX'S ANTI-vWF NANOBODY, CAPLACIZUMAB, PRESENTED AT THE AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING
            

Phase III data shows Sandoz' investigational biosimilar filgrastim has similar safety and efficacy as Amgen's NEUPOGEN®
Novartis International AG /Phase III data shows Sandoz' investigational biosimilar filgrastim has similar safety and efficacy as Amgen's NEUPOGEN® . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Novartis highlights new CTL019 clinical data showing complete remissions in children and young adults with relapsed/refractory acute lymphoblastic leukemia
Novartis International AG /Novartis highlights new CTL019 clinical data showing complete remissions in children and young adults with relapsed/refractory acute lymphoblastic leukemia . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Proteostasis Therapeutics Announces Appointment of Dr. Po-Shun Lee as Vice President of Clinical Development
Proteostasis Therapeutics, Inc., a company developing novel therapeutics that regulate protein homeostasis to improve outcomes for patients with orphan and neurodegenerative diseases, today announced the appointment of Dr. Po-Shun Lee, MD, as Vice President of Clinical Development. Dr

Novartis features innovative immunotherapy, targeted pipeline treatment combinations and long-term data at ASH and SABCS 2014
Novartis International AG /Novartis features innovative immunotherapy, targeted pipeline treatment combinations and long-term data at ASH and SABCS 2014 . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Regen BioPharma Scheduled to Make Presentation at American Society for Hematology's 56th Annual Meeting in San Francisco December 6th - 9th
Regen BioPharma (OTCBB: RGBP) announced today acceptance by the American Society for Hematology of a presentation by Christine Ichim, PhD, senior scientific research consultant to Regen BioPharma, at its annual meeting entitled "NR2F6 (EAR-2) Is a Novel Leukemia Oncogene Whose Cellular Function Is to Regulate Terminal Differentiation of Erythrocytes at the Proerythroblast Stage

Sandoz begins Phase III clinical trial for biosimilar adalimumab
Novartis International AG /Sandoz begins Phase III clinical trial for biosimilar adalimumab. Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Sandoz receives first approval for AirFluSal® Forspiro®
Novartis International AG /Sandoz receives first approval for AirFluSal® Forspiro®. Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

BrightScope Announces Its Fifth Annual Year-End Top 30 401k Plans List
BrightScope (www.brightscope.com), the leading provider of independent retirement plan ratings and investment research, is proud to announce the fifth annual BrightScope Year-End Top 30 Ratings List covering 401k plans with more than $1 billion in assets

BariaMed(R) Program, Designed to Improve Post-Bariatric Surgery Outcomes, Has Been Announced
A new program, BariaMed®, will incorporate a serious game and a connected spoon, BariaSpoon®, to support patients in their nutritional and behavioral rehabilitation after bariatric (obesity) surgery. BariaMed is a program that offers a behavior-change tool, software that collects data, nutrition products and oversight by a medical specialist.

Alzheimer's Foundation of America Releases 'A Roadmap to Alzheimer's Disease & Driving' DVD
NEW YORK, NY--(Marketwired - December 12, 2013) - "Taking away the keys" often is one of the most difficult decisions family and professional caregivers of individuals with Alzheimer's disease and related illnesses face as symptoms progress to the point that drivers with the brain disorder pose a potential danger on the road -- to themselves and others

Novartis supplies MenB vaccine, Bexsero®, to Princeton University to help protect students from potentially deadly outbreak
Novartis International AG /Novartis supplies MenB vaccine, Bexsero®, to Princeton University to help protect students from potentially deadly outbreak . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

New five-year data support superiority of Novartis drug Tasigna® over Glivec® in newly diagnosed Ph+ CML patients
Novartis International AG /New five-year data support superiority of Novartis drug Tasigna® over Glivec® in newly diagnosed Ph+ CML patients . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
Novartis International AG /Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Vista Partners Publishes December 2013 Macroeconomic & Investment Newsletter
Vista Partners ("Vista") announced today that it published its FREE Macroeconomic & Investment Monthly Newsletter for the month of December. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary.

Novartis investigational compound LBH589 significantly extended time without disease progression in Phase III multiple myeloma study
Novartis International AG /Novartis investigational compound LBH589 significantly extended time without disease progression in Phase III multiple myeloma study . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Novartis Africa Day highlights company's efforts to expand access to healthcare
Novartis International AG /Novartis Africa Day highlights company's efforts to expand access to healthcare. Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Novartis to highlight long-term data, innovative pipeline for patients with hematologic diseases and breast cancer at ASH and SABCS
Novartis International AG /Novartis to highlight long-term data, innovative pipeline for patients with hematologic diseases and breast cancer at ASH and SABCS . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Publicis Groupe : Acquisition of Synergize, a South African Agency
PUBLICIS GROUPE ACQUIRES LEADING DIGITAL MARKETING AGENCY 'SYNERGIZE' IN SOUTH AFRICA

Novartis Foundation launches new leprosy strategy at symposium on disease elimination
Novartis International AG /Novartis Foundation launches new leprosy strategy at symposium on disease elimination . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

New malaria target identified with potential to prevent, block, and treat multiple stages of the malaria life cycle
Novartis International AG /New malaria target identified with potential to prevent, block, and treat multiple stages of the malaria life cycle . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Hamilton Thorne Announces 2013 Third Quarter Financial Results
Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision laser devices and advanced image analysis systems for living cell applications in the fertility, stem cell and developmental biology research markets, today reported operational and financial results for the third quarter and nine month period ended September 30, 2013.

Vernalis Announces Successful Study With CCP-01

Novartis highlights growth prospects driven by significant R&D pipeline progress and the expected increase in blockbuster treatments
Novartis International AG /Novartis highlights growth prospects driven by significant R&D pipeline progress and the expected increase in blockbuster treatments . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Urgency of Improving Information Economics Sparks Major Growth in CGOC Community

Cornerstone Therapeutics Launches BETHKIS(R) (Tobramycin Inhalation Solution) for Management of Cystic Fibrosis Patients With Pseudomonas Aeruginosa
Cornerstone Therapeutics Inc. (NASDAQ: CRTX) announced today the launch of BETHKIS® (Tobramycin Inhalation Solution), a nebulized therapy indicated for the management of cystic fibrosis (CF) patients with Pseudomonas aeruginosa

Novartis drug Exjade® approved by European Commission for iron overload in patients with non-transfusion-dependent thalassemia
Novartis International AG /Novartis drug Exjade® approved by European Commission for iron overload in patients with non-transfusion-dependent thalassemia . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Market for Kinase Inhibitors Heats Up: Kalorama
The cancer kinase inhibitor market is estimated at $12.1 billion worldwide for 2012, representing annual revenue growth of 16.9% over 2007. The effectiveness of kinase inhibitors has sparked interest from major pharmaceutical companies, according to the healthcare market research publisher, Kalorama Information

Pharma-Biotech Industry Invests More Than $12 Billion in 2012 North American Project Starts, an Industrial Info News Alert
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- As the last moments of 2012 run their course, it is a good time to take a look at the Pharmaceutical-Biotech Industry's capital and maintenance (MRO) project activity for the year. In January, the industry had a whopping $17 billion worth of projects set to launch construction in 2012

Poxel Raises €13 million to Progress Imeglimin Development to Treat Type 2 diabetes
Poxel S.A. /Poxel Raises €13 million to Progress Imeglimin Development to Treat Type 2 diabetes . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder
Novartis International AG /Novartis drug Signifor® gains FDA approval as the first medication to treat Cushing's disease, a serious endocrine disorder . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Two-year data show new Novartis drug Jakavi® significantly reduced myelofibrosis disease burden and suggest overall survival advantage
Novartis International AG /Two-year data show new Novartis drug Jakavi® significantly reduced myelofibrosis disease burden and suggest overall survival advantage . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Novartis long-term Phase III data show Ph+ CML patients on Tasigna® achieved significantly deeper molecular response versus Glivec®
Novartis International AG /Novartis long-term Phase III data show Ph+ CML patients on Tasigna® achieved significantly deeper molecular response versus Glivec® . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Prize4Life Announces the Launch of PRO-ACT: The Largest ALS Clinical Trials Database Ever Created
Prize4Life, a nonprofit organization whose mission is to accelerate the discovery of treatments and a cure for ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig's disease), announced today the launch of the PRO-ACT (Pooled Resource Open-Access ALS Clinical Trials) database, the largest ALS clinical trial database ever created.

Noble Financial Capital Markets Appoints Healthcare Scientific Advisory Board
Noble Financial Capital Markets (Noble) announced today that it has established a scientific advisory board (SAB). Jules Musing, a Large Pharma veteran who will chair the Board, is excited about the developmental prospects for the SAB. "Establishment of this Board represents a bold strategic initiative for Noble," said Musing

Vista Partners Publishes December 2012 Newsletter
Vista Partners ("Vista") announced today that it published its FREE macroeconomic/small cap oriented monthly newsletter for the month of December. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst, Ross Silver, and monthly highlights of each covered small cap company.

Essex Woodlands Opens New International Office in Shanghai to Invest in Rapidly Growing Chinese Healthcare Companies
Essex Woodlands, a leading healthcare growth capital firm with a global investment practice, announced today the opening of a new office in Shanghai, China. The Shanghai office will lead Essex Woodlands' healthcare investment practice in China, focusing on Pharmaceuticals, Medical Technology, Services, and Information Technology

Hamilton Thorne Announces 2012 Third Quarter Financial Results
Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision laser devices and advanced image analysis systems for the fertility, stem cell and developmental biology research markets, today reported operational and financial results for the third quarter and nine months year-to-date ended September 30, 2012.

Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS
Novartis International AG /Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

ABLYNX AND ALGETA ENTER INTO A RESEARCH COLLABORATION TO EVALUATE THE POTENTIAL OF NOVEL ALPHA-PHARMACEUTICALS COMPRISING THORIUM-277 CONJUGATED TO TUMOUR-TARGETING NANOBODIES
GHENT, Belgium and OSLO, Norway, 21 November 2012 - Ablynx [Euronext Brussels: ABLX] and Algeta ASA [OSE: ALGETA] announce a research collaboration to evaluate a novel Targeted Thorium Conjugate (TTC) based on combining Algeta's proprietary thorium-227 alpha-pharmaceutical payload with Nanobodies® generated using Ablynx's proprietary technology platform.

Algeta and Ablynx enter into a research collaboration to evaluate the potential of novel alpha-pharmaceuticals comprising thorium-227 conjugated to tumor-targeting Nanobodies®
Oslo, Norway, and Ghent, Belgium, 21 November 2012 - Algeta ASA (OSE: ALGETA) and Ablynx (Euronext Brussels: ABLX) announce a research collaboration to evaluate a novel Targeted Thorium Conjugate (TTC) based on combining Algeta's proprietary thorium-227 alpha-pharmaceutical payload with Nanobodies® generated using Ablynx's proprietary technology platform.

Novartis receives FDA approval for Flucelvax®, the first cell-culture vaccine in US to help protect against seasonal influenza
Novartis International AG /Novartis receives FDA approval for Flucelvax®, the first cell-culture vaccine in US to help protect against seasonal influenza . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Novartis receives positive CHMP opinion for Bexsero®, a groundbreaking vaccine to help prevent devastating MenB infections, the leading cause of meningitis in Europe
Novartis International AG /Novartis receives positive CHMP opinion for Bexsero®, a groundbreaking vaccine to help prevent devastating MenB infections, the leading cause of meningitis in Europe . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Novartis drug Exjade® recommended by CHMP for EU approval to treat patients with non-transfusion-dependent thalassemia syndromes
Novartis International AG /Novartis drug Exjade® recommended by CHMP for EU approval to treat patients with non-transfusion-dependent thalassemia syndromes . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

ABLYNX PROVIDES BUSINESS UPDATE FOR THE FIRST NINE MONTHS OF 2012
REGULATED INFORMATION

Novartis new two-year data with Certican® shows positive outcomes at 24 months in largest liver transplant trial to date
Novartis International AG /Novartis new two-year data with Certican® shows positive outcomes at 24 months in largest liver transplant trial to date . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

BrightScope Announces Its Third Annual Year-End Top 30 401k Plans List
BrightScope (www.brightscope.com), the leading provider of independent retirement plan ratings and investment research, is proud to announce the third annual BrightScope Year-End Top 30 Ratings List covering 401k plans with more than $1 billion in assets

Novartis announces termination of ALTITUDE study with Rasilez®/ Tekturna® in high-risk patients with diabetes and renal impairment
Novartis International AG /Novartis announces termination of ALTITUDE study with Rasilez®/ Tekturna® in high-risk patients with diabetes and renal impairment . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

FFF Enterprises Launches 2012-13 MyFluVaccine Ordering With Expanded Portfolio
FFF Enterprises, Inc., the nation's largest and most trusted distributor of flu vaccine, announced today that its expanded portfolio of flu vaccine for the 2012-13 flu season is now available for purchase. Customers who order early can choose their preferred delivery dates to match their vaccination schedule.

Cegedim Strategic Data (CSD) ranks pharmaceutical companies' social media presence
Cegedim StrategicData(CSD), leading provider ofintegrated healthcare market research and worldwide promotional audits, hasinitiated a study comparing the ranking of pharmaceutical companies' spendontraditional promotional channels to their presence on two leading socialmediachannels - Facebook and Twitter.

Novartis drug Gilenya® showed positive clinical outcomes for relapsing-remitting MS patients in third large Phase III clinical trial
Novartis International AG /Novartis drug Gilenya® showed positive clinical outcomes for relapsing-remitting MS patients in third large Phase III clinical trial . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Novartis pivotal study of Exjade® shows significant reduction of iron overload in patients with non-transfusion-dependent thalassemia
Novartis International AG /Novartis pivotal study of Exjade® shows significant reduction of iron overload in patients with non-transfusion-dependent thalassemia . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

New Phase III data shows Novartis JAK inhibitor INC424 significantly reduced disease burden in patients with myelofibrosis
Novartis International AG /New Phase III data shows Novartis JAK inhibitor INC424 significantly reduced disease burden in patients with myelofibrosis . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Two Novartis Phase III studies show twice as many Ph+ CML patients achieve deeper levels of response with Tasigna® compared to Glivec®
Novartis International AG /Two Novartis Phase III studies show twice as many Ph+ CML patients achieve deeper levels of response with Tasigna® compared to Glivec® . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

New data confirms Novartis drug Afinitor® significantly extends time women with advanced breast cancer live without tumor growth
Novartis International AG /New data confirms Novartis drug Afinitor® significantly extends time women with advanced breast cancer live without tumor growth . Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

New drugs show promise against advanced breast cancer
Scientists have found two new medicines that could keep breast cancer in check.

Comment on this story

Share